AstraZeneca’s Farxiga demonstrated what the company called an “unprecedented reduction” in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease.
Farxiga is the first medicine to significantly prolong survival in a renal outcomes trial in patients with chronic kidney disease with and without type-2 diabetes
Detailed results from the late-stage DAPA-CKD trial showed that AstraZeneca’s Farxiga (dapagliflozin) on top of the standard of care reduced measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39 percent compared to placeboin patients with chronic kidney disease in stages 2-4.
The results were consistent in patients both with and without type-2 diabetes.
CKD is a serious, progressive condition defined by decreased kidney function affecting nearly 700 million people worldwide, many of them still undiagnosed.
The co-chairs of the trial and its Executive Committee Prof. David Wheeler, University College London and Prof. Hiddo L. Heerspink, University Medical Center Groningen, the Netherlands, said: “The impressive DAPA-CKD trial results are a remarkable development for patients with chronic kidney disease. These data have the potential to transform the standard of care for this patient population, which has a significant unmet need for new and improved treatment options.”
In the trial, patients treated with Farxiga experienced fewer serious adverse events compared to placebo.
In May 2020, Farxiga was approved in the US to reduce the risk of death and hospitalization for heart failure in adults with heart failure.
Farxiga is taken orally once a day.
AstraZeneca employs 1,500 in northern Delaware.